GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adial Pharmaceuticals Inc (NAS:ADILW) » Definitions » Debt-to-Asset

Adial Pharmaceuticals (Adial Pharmaceuticals) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adial Pharmaceuticals Debt-to-Asset?

Adial Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Adial Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Adial Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $6.68 Mil. Adial Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Adial Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Adial Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adial Pharmaceuticals Debt-to-Asset Chart

Adial Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only - - 0.03 0.04 -

Adial Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 - - - -

Competitive Comparison of Adial Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Adial Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adial Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adial Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Adial Pharmaceuticals's Debt-to-Asset falls into.



Adial Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Adial Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Adial Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adial Pharmaceuticals  (NAS:ADILW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Adial Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Adial Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Adial Pharmaceuticals (Adial Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1180 Seminole Trail, Suite 495, Charlottesville, VA, USA, 22901
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Adial Pharmaceuticals (Adial Pharmaceuticals) Headlines

From GuruFocus